Aravive, Inc., a clinical-stage biopharmaceutical company based in Houston, Texas, is making strides in developing transformative treatments for life-threatening diseases such as cancer and fibrosis. Aravive's lead product candidate, batiraxcept, is an ultrahigh-affinity decoy protein that targets the GAS6-AXL signaling pathway. Batiraxcept is currently in Phase III clinical trial for the treatment of platinum-resistant recurrent ovarian cancer, and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. In addition to batiraxcept, Aravive is also developing AVB-S6, a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway. Aravive holds a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, the company has entered into a license agreement with 3D Medicines Inc. to develop products containing batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. Previously known as Versartis, Inc., Aravive changed their name in October 2018 to better reflect their focus on innovative therapeutic candidates. Aravive was incorporated in 2008 and continues to prioritize the development of groundbreaking treatments for a range of deadly diseases.
Aravive, Inc.'s ticker is ARAV
The company's shares trade on the NASDAQ stock exchange
They are based in Houston, Texas
There are 11-50 employees working at Aravive, Inc.
It is https://aravive.com/
Aravive, Inc. is in the Healthcare sector
Aravive, Inc. is in the Biotechnology industry
The following five companies are Aravive, Inc.'s industry peers: